期刊文献+

左乙拉西坦添加治疗部分性癫痫的临床观察 被引量:4

Levetiracetam as an addictive therapy for partial seizures
原文传递
导出
摘要 目的观察左乙拉西坦(LEV)对儿童及成人难治性部分性癫痫的疗效和安全性。方法在原服用抗癫痫药(AEDs)不变的基础上加服LEV,起始剂量:成人500mg,每日2次,儿童10ms/(kg·d),根据疗效调整剂量,比较不同年龄、病程、发作频率患者的疗效。结果59例难治性部分性癫痫患者加用LEV后无发作7例(11.9%),有效19例(32.2%),无效33例(55.9%),LEV对儿童和成人、不同病程及发作频率的癫痫患者疗效比较差异无统计学意义(P〉0.05)。有10例(16.9%)出现与LEV可能有关的不良反应,其中嗜睡3例,急躁3例,注意力不集中、记忆力下降、反应迟钝、攻击行为各1例,上述不良反应均未经特殊处理,在1~2个月内自行消失,无一例因不良反应退出治疗。结论LEV对难治性部分性癫痫患者安全有效,可以用作难治性部分性癫痫的加用治疗。 Objective To observe the efficacy and safety of levetiracetam(LEV) in children and adults with refractory partial seizures. Methods The patients with refractory partial epilepsies who had their present AEDs as usual received LEV as an add - on treatment. The starting dose in adults was 500 rag,bid and in children was 10 mg/(kg.d). It adjusted the dose basing on the efficacy. And comparing the efficacy in different ages, different courses and different seizure frequencies. Results Seven (11.9%) patients in 59 patients became seizure free, 19 (32.2%) was effective, 33(55.9% ) was ineffective. There was no difference on efficacy between children and adults patients, also in different courses and different seizure frequencies. Adverse reaction: 10( 16.9% ) patients had the adverse reactions related to LEV; and 3 of them were drowsiness, and 3 were restless, and impaired concentration, bad remembrance, reaction slow and aggressive behavior had one. They all disappeared in 1 to 2 months with no special handling. No person signed off because of adverse reaction. Conclusions LEV proved to be an effective and safe treatment in patients with refractory partial seizures and can be an add -on treatment for refractory partial seizures.
出处 《中国实用医刊》 2009年第7期7-8,12,共3页 Chinese Journal of Practical Medicine
关键词 左乙拉西坦 添加治疗 部分性癫痫 临床观察 Levetiracetam Addictive therapy Partial seizures Clinical observation
  • 相关文献

同被引文献31

  • 1邹丽萍,伍云.抗癫痫新药儿科应用研究进展[J].世界临床药物,2004,25(6):330-333. 被引量:6
  • 2田国红,赵忠新.左乙拉西坦——一种具有全新作用机制的抗癫痫新药[J].中国新药与临床杂志,2006,25(10):782-786. 被引量:43
  • 3林庆.实用小儿癫痫病学[M]北京:北京科学技术出版社,2004.
  • 4Lynch BA,Lambeng N,Nocka K. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam[J].Proceedings of the National Academy of Sciences(USA),2004,(26):9861-9866.
  • 5Striano P,Goppola A,Pezzela M. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy[J].Neurology,2007,(03):250-254.
  • 6Grosso S,Cordellid M,Franaoni E. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy[J].Seizure-European Journal of Epilepsy,2007,(04):345-350.
  • 7Grosso S,Franzoni E,Coppola G. Efficacy and safety of levetiracetam:an add-on trial in children with refactoryepilepsy[J].Seizure-European Journal of Epilepsy,2005,(04):248-253.
  • 8Mikati MA,ElBanna D,Sinno D. Response of infantile spasms to levetiracetam[J].Neurology,2008,(07):574-575.
  • 9Ilo E,Leppik C. The pace of levetiracetam in the treatment of epilepsy[J].Epilepsia,2001,(z4):44-45.
  • 10Zona C,Niespodziany I,Marchetti C. Levetiracetam does not modulate neuronal voltage-gated Na and T-type Ca currents[J].Seizure-European Journal of Epilepsy,2001,(04):279-286.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部